skip to content

Cambridge Immunology Network

 

Nerve growth factor β plays an unexpected Spaetzle-like role in immunity to Staphylococcus aureus infection

31 October 2014

"A Spaetzle-like role for nerve growth factor β in vertebrate immunity to Staphylococcus aureus" in Science this week

Read more

Some pictures from CIF14 online

14 October 2014

Some snapshots taken during the coffee breaks, see this link

Read more

Clare Bryant wins Alzheimer's Research UK's Interdisciplinary Research Grants

Clare Bryant wins Alzheimer's Research UK's Interdisciplinary Research Grants

2 October 2014

Professor Clare Bryant has been awarded one of Alzheimer's Research UK's first ever Interdisciplinary Research Grants, bringing her expertise in immunology to a new collaboration in dementia research.

Read more

Andres Floto has been appointed as Professor of Respiratory Biology

1 October 2014

Andres Floto has been appointed as Professor of Respiratory Biology

Read more

The Cambridge Immunology Network has a new chair

26 September 2014

Arthur Kaser and Clare Bryant are the new chair and deputy chair for the Cambridge Immunology Network

Read more

The Cambridge Institute of Therapeutic Immunology and Infectious Disease is coming

16 July 2014

Cambridge Institute of Therapeutic Immunology and Infectious Disease receives £25 million of government funding

Read more

Inactivation of phosphoinositide-3-OH kinase δ as a possible cancer treatment in Nature this week

Inactivation of phosphoinositide-3-OH kinase δ as a possible cancer treatment in Nature this week

12 June 2014

Phosphoinositide-3-OH kinase δ restrains the anti-tumour immune response by promoting the action of suppressive immune cells

Read more

Alemtuzumab is approved by NICE for treatment of MS

Alemtuzumab is approved by NICE for treatment of MS

1 June 2014

A drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.

Read more

Immunology PhD and Postdoc Day

Immunology PhD and Postdoc Day

15 April 2014

29 May 2014, Sainsbury Centre, Bateman Street, all day scientific presentations and posters from Cambridge Immunology PhD students and postdocs.

Read more

Peanut Allergy Trial

Peanut Allergy Trial

30 January 2014

A report on a randomised trial using to relieve peanut allergies in children was published in the Lancet today and received extensive publicity

Read more